Real-world effectiveness of eribulin in heavily pretreated patients with metastatic breast cancer in China: a multicenter retrospective study

Abstract

Background: Eribulin is a nontaxane microtubule inhibitor approved in China for patients with advanced breast cancer who show progression after ⩾2 lines of chemotherapy. The aim of this study was to determine the efficacy and safety profile of eribulin and explore potential predictive factors for the efficacy of eribulin among Chinese women with metastatic breast cancer (MBC) in real-world practice. Patients and Methods: A total of 272 consecutive MBC patients who were treated with eribulin between November 2019 and October 2020 in 9 institutions nationwide were included in this study. Eribulin was administered intravenously at a dose of 1.4 mg/m2 on days 1 and 8 of a 21-day cycle. Efficacy outcomes included progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and clinical benefit rate (CBR). Adverse events (AEs) were graded according to The National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 5.0. Results: Eribulin showed a median PFS of 4.1 months (95% confidence interval [CI] 3.6–4.6); however, the OS data were immature. The ORR was 17.6% and the CBR was 24.6%. A total of 51.8% of patients received eribulin monotherapy, while 48.2% of patients were treated with eribulin plus targeted therapy or other chemotherapy. The number of metastatic sites, duration of previous taxane treatment for MBC, and combination with bevacizumab were significant in Cox multivariate analysis ( p = 0.023, p = 0.048, and p = 0.046, respectively) and were significantly associated with PFS of eribulin. The most common AEs with eribulin treatment were hematological toxicities, including neutropenia, leukopenia, and anemia. Conclusion: Eribulin was effective with a manageable toxicity profile in clinical practice. Furthermore, when prescribed in combination with other agents, eribulin did not increase the toxic effects of each agent. Eribulin monotherapy or plus other agents is an alternative for the heavily pretreated patients with MBC.

Average duration of prior treatment lines predicts clinical benefit to eribulin chemotherapy in patients with metastatic breast cancer

“…The results of the prognostic analyses in the study were largely unchanged after exclusion of these individuals (data not shown). Other trials based on real-world data including > 100 patients report a wider spread of results for PFS (3.3-6.1 months) and OS (10.6-31.8 months) [7][8][9][10][11][12][13][14]. Differences in PFS could result from less frequent imaging or patient and tumour variability as well as differences in previous lines of MBC treatment between the cohorts.…”

Efficacy of albumin-bound paclitaxel combined with nedaplatin in neoadjuvant therapy for esophageal squamous cell carcinoma: A single-center retrospective observational study

“…Adverse events for chemotherapy regimens were applicable to the National Cancer Institute Common Toxicity Criteria 5.0, which could be applied to grades 1 to 5 according to severity. [15]…”

10 years of success achieved by eribulin while treating HER2-negative mBC: from randomized studies to routine practice

“…Медиана числа предшествующих линий химиотерапии по поводу распространенной стадии достигла 5; эрибулин назначался в качестве 3-й линии всего у 13,1 % больных, в качестве 4-й линии -у 19,3 %, в качестве 5-й и более поздних линий терапиив 60,4 % случаев. Медиана числа проведенных циклов терапии эрибулином составила 4 (1)(2)(3)(4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20). Медиана ОВ достигла 12,6 мес при назначении эрибулина в 3-й линии, 11,5 мес -в 4-й линии, и составила 9,7 мес при назначении в 5-й и более поздних линиях лечения.…”

“…В 2021 г. были представлены результаты крупного мультицентрового ретроспективного исследования, в котором 272 пациента получали химиотерапию эрибулином с ноября 2019 г. по октябрь 2020 г. в 9 институтах Китая [16]. Медиана числа предшествующих эрибулину линий химиотерапии составила 4 (2-5); 94,9 % больных получали ранее таксаны, 82,7 % -антрациклины.…”

“…Обзорные статьи против 3,7 мес, p = 0,048). Профиль безопасности терапии был весьма благоприятным: наиболее частыми нежелательными явлениями III-IV степени тяжести были нейтропения (18 %), лейкопения (5,5 %) и анемия (1,1 %); случаи нейропатии были редки (всего 1,1 %); редукция дозы эрибулина потребовалась всего в 7 % случаев [16].…”